What do systematic reviews say?

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… showed no clear difference in total number of new lesions over 2-month treatment period compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -0.30 [-0.90, 0.30]
  1 study · 40 participants
  GRADE not reported

Colchicine (0.5 mg three times per day) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 months
  There was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P=0.009). The review noted potential evidence of harm at a dose of 1.5 mg…
  1 study · 43 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  The study reported more drug-related adverse effects for those treated with prednisone than montelukast.
  1 study · 40 participants
  GRADE not reported

Pilocarpine lozenge (3 mg or 5 mg) vs placebo control

• Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes

  Single dose (up to 3 hours)
  Taweechaisupapong 2006 (crossover): participants reported a statistically significant improvement in oral dryness after both 3 mg and 5 mg pilocarpine lozenges vs placebo (P <= 0.05); no usable data presented. No…
  1 study · 33 participants
  GRADE not reported

Pilocarpine lozenge (3 mg or 5 mg) vs placebo control

• Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes

  Single dose (up to 3 hours)
  Statistically significant increase in saliva production vs placebo (P <= 0.05); maximum salivary output 60 to 90 minutes post-lozenge; no data presented.
  1 study · 33 participants
  GRADE not reported

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 80 participants
  Moderate

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Low

Summary of findings: 5 mg/day vs placebo

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in headache ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 1.73 [0.92, 3.24]
  1 study · 53 participants
  Low

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in rash ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 3.12 [0.35, 28.06]
  1 study · 53 participants
  Low

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

It is very uncertain whether summary of findings: 5 mg/day changes headache ( compared with injection with corticosteroid and anaesthetic (very low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 31.003 [1.96, 490.31]
  1 study · 48 participants
  Very low

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

It is very uncertain whether summary of findings: 5 mg/day changes injection site pain ( compared with injection with corticosteroid and anaesthetic (very low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 0.11 [0.01, 1.96]
  1 study · 48 participants
  Very low

Summary of findings: 5 mg/day vs placebo

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low

Summary of findings: 5 mg/day vs placebo

It is very uncertain whether summary of findings: 5 mg/day changes symptom free ( compared with placebo (very low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 1.91 [1.04, 3.5]
  1 study · 20 participants
  Very low